Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 46, Issue , 2013, Pages 43-47

  Gomes, Felipe V ^a   Del Bel, Elaine A ^a   Guimarães, Francisco S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

5 HT1A receptor; Cannabidiol; Cannabinoids; Catalepsy test; Striatal disorders

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; RECEPTOR BLOCKING; RECEPTOR UPREGULATION;

Δ(9)-TETRAHYDROCANNABINOL; Δ(9)-THC; 5-HT1A RECEPTOR; CANNABIDIOL; CANNABINOIDS; CATALEPSY TEST; CBD; L-NITRO-N-ARGININE; L-NOARG; NITRIC OXIDE; NITRIC OXIDE SINTHASE; NO; NOS; STRIATAL DISORDERS;

ANIMALS; CANNABIDIOL; CATALEPSY; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; NITRIC OXIDE SYNTHASE; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 84880360557     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.06.005     Document Type: Article

References (58)

1. Abdel-Salam O.M.E., El-Shamarka M.E., Salem N.A., Gaafar A.E.M. Effects of Cannabis sativa extract on haloperidol-induced catalepsy and oxidative stress in the mice. EXCLI J 2012, 11:45-58.
2. Bartoszyk G.D., Roos C., Ziegler H. 5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacology 1996, 35:1645-1646.
3. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001, 134:845-852.
4. Campos A.C., Guimaraes F.S. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 2008, 199:223-230.
5. Campos A.C., Moreira F.A., Gomes F.V., Del Bel E.A., Guimaraes F.S. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012, 367:3364-3378.
6. Carrier E.J., Auchampach J.A., Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 2006, 103:7895-7900.
7. Casarotto P.C., Gomes F.V., Resstel L.B., Guimaraes F.S. Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol 2010, 21:353-358.
8. Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 1992, 260:201-209.
9. Consroe P., Sandyk R., Snider S.R. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986, 30:277-282.
10. Deiana S., Watanabe A., Yamasaki Y., Amada N., Arthur M., Fleming S., et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 2012, 219:859-873.
11. Del Bel E.A., da Silva C.A., Guimaraes F.S. Catalepsy induced by nitric oxide synthase inhibitors. Gen Pharmacol 1998, 30:245-248.
12. Del Bel E.A., Souza A.S., Guimaraes F.S., da-Silva C.A., Nucci-da-Silva L.P. Motor effects of acute and chronic inhibition of nitric oxide synthesis in mice. Psychopharmacology (Berl) 2002, 161:32-37.
13. Del Bel E.A., da Silva C.A., Guimaraes F.S., Bermudez-Echeverry M. Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. Eur J Pharmacol 2004, 485:175-181.
14. Echeverry M.B., Salgado M.L., Ferreira F.R., da-Silva C.A., Del Bel E.A. Intracerebroventricular administration of nitric oxide-sensitive guanylyl cyclase inhibitors induces catalepsy in mice. Psychopharmacology (Berl) 2007, 194:271-278.
15. Egashira N., Matsuda T., Koushi E., Mishima K., Iwasaki K., Shoyama Y., et al. Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. Eur J Pharmacol 2006, 550:117-122.
16. Fernandes M., Schabarek A., Coper H., Hill R. Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat. Psychopharmacologia 1974, 38:329-338.
17. Formukong E.A., Evans A.T., Evans F.J. Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L. J Pharm Pharmacol 1988, 40:132-134.
18. Garcia-Arencibia M., Gonzalez S., de Lago E., Ramos J.A., Mechoulam R., Fernandez-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 2007, 1134:162-170.
19. Gomes F.V., Resstel L.B., Guimaraes F.S. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology (Berl) 2011, 213:465-473.
20. Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Prog Neurobiol 1998, 56:507-540.
21. Hayakawa K., Mishima K., Hazekawa M., Sano K., Irie K., Orito K., et al. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 2008, 1188:157-164.
22. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990, 87:1932-1936.
23. Hicks P.B. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 1990, 47:1609-1615.
24. Invernizzi R.W., Cervo L., Samanin R. 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 1988, 27:515-518.
25. Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009, 30:515-527.
26. Jones G., Pertwee R.G. A metabolic interaction in vivo between cannabidiol and 1-tetrahydrocannabinol. Br J Pharmacol 1972, 45:375-377.
27. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
28. Karniol I.G., Carlini E.A. Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia 1973, 33:53-70.
29. Karniol I.G., Shirakawa I., Kasinski N., Pfeferman A., Carlini E.A. Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol 1974, 28:172-177.
30. 9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) 2011, 218:443-457.
31. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005, 19:96-107.
32. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012, 2:e94.
33. Marchese G., Casti P., Ruiu S., Saba P., Sanna A., Casu G., et al. Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. Br J Pharmacol 2003, 140:520-526.
34. Marras R.A., Martins A.P., Del Bel E.A., Guimaraes F.S. L-NOARG, an inhibitor of nitric oxide synthase, induces catalepsy in mice. Neuroreport 1995, 7:158-160.
35. Martin-Calderon J.L., Munoz R.M., Villanua M.A., del Arco I., Moreno J.L., de Fonseca F.R., et al. Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 1998, 344:77-86.
36. Mauler F., Mittendorf J., Horvath E., De Vry J. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 2002, 302:359-368.
37. McMahon L.R., Koek W. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. Eur J Pharmacol 2007, 569:70-76.
38. Mechoulam R. Marihuana chemistry. Science 1970, 168:1159-1166.
39. Moreira F.A., Guimaraes F.S. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005, 512:199-205.
40. Murillo-Rodríguez E., Millám-Aldaco D., Palomero-Rivero M., Mechoulam R., Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 2006, 580:4337-4345.
41. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993, 265:207-217.
42. Nucci-da-Silva L.P., Guimaraes F.S., Del Bel E.A. Serotonin modulation of catalepsy induced by N(G)-nitro-L-arginine in mice. Eur J Pharmacol 1999, 379:47-52.
43. Pava M.J., Blake E.M., Green S.T., Mizroch B.J., Mulholland P.J., Woodward J.J. Tolerance to cannabinoid-induced behaviors in mice treated chronically with ethanol. Psychopharmacology (Berl) 2012, 219:137-147.
44. Prinssen E.P., Colpaert F.C., Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 2002, 453:217-221.
45. Rock E.M., Bolognini D., Limebeer C.L., Cascio M.G., Anavi-Goffer S., Fletcher P.J., et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2012, 165:2620-2634.
46. Russo E.B., Burnett A., Hall B., Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005, 30:1037-1043.
47. Sanberg P.R., Bunsey M.D., Giordano M., Norman A.B. The catalepsy test: its ups and downs. Behav Neurosci 1988, 102:748-759.
48. Sandor N.T., Brassai A., Puskas A., Lendvai B. Role of nitric oxide in modulating neurotransmitter release from rat striatum. Brain Res Bull 1995, 36:483-486.
49. Sano K., Mishima K., Koushi E., Orito K., Egashira N., Irie K., et al. Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience 2008, 151:320-328.
50. Thomas A., Baillie G.L., Phillips A.M., Razdan R.K., Ross R.A., Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007, 150:613-623.
51. Varvel S.A., Wiley J.L., Yang R., Bridgen D.T., Long K., Lichtman A.H., et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl) 2006, 186:226-234.
52. Vincent S.R., Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 1992, 46:755-784.
53. Zanelati T.V., Biojone C., Moreira F.A., Guimaraes F.S., Joca S.R. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 2010, 159:122-128.
54. Zuardi A.W., Finkelfarb E., Bueno O.F., Musty R.E., Karniol I.G. Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol. Arch Int Pharmacodyn Ther 1981, 249:137-146.
55. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982, 76:245-250.
56. Zuardi A.W., Rodrigues J.A., Cunha J.M. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991, 104:260-264.
57. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., Guimaraes F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006, 39:421-429.
58. Zuardi A.W., Crippa J.A., Hallak J.E., Pinto J.P., Chagas M.H., Rodrigues G.G., et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2009, 23:979-983.